Exosome Research Global Market Report 2024

The exosome research market has grown exponentially in recent years. It will grow from $210.62 billion in 2023 to $283.43 billion in 2024 at a compound annual growth rate (CAGR) of 34.6%. The expansion observed in the historical period can be ascribed to an enhanced comprehension of exosome biology, augmented investment in life sciences research, the advent of liquid biopsies, a heightened emphasis on personalized medicine, and collaborative research initiatives.

The exosome research market is expected to see exponential growth in the next few years. It will grow to $865.26 billion in 2028 at a compound annual growth rate (CAGR) of 32.2%. The anticipated growth in the forecast period can be ascribed to the clinical translation of exosome-based therapeutics, the broadening scope of liquid biopsy applications, heightened collaboration within the industry for research purposes, growing interest in extracellular vesicles (EVs), and an emphasis on standardization and quality control. Major trends expected in the forecast period include advancements in clinical applications and therapeutics, technological progress in isolation and analysis methods, discoveries in biomarker identification and diagnostics, a focus on standardization and quality control, as well as increased collaborations and partnerships.

The anticipated growth in the exosome research market is attributed to the increased incidence of chronic medical diseases. Chronic diseases, lasting three months or longer and often worsening over time, include common ailments such as cancer, heart disease, stroke, diabetes, and arthritis. The release of exosomes can be exploited by infections to avoid immune system detection, highlighting the significance of exosome research in understanding and addressing various diseases, including cancer, neurodegenerative disorders, and inflammatory conditions. For instance, a report from the Centers for Disease Control and Prevention in July 2022 revealed that 6 out of 10 Americans suffer from chronic diseases, with 4 out of 10 adults experiencing more than two chronic conditions, such as chronic lung disease, heart disease, stroke, and diabetes. Consequently, the increased incidence of chronic medical diseases is set to drive the growth of the exosome research market.

The expected rise in funding for life sciences research is another factor contributing to the growth of the exosome research market. Funding for life sciences research involves financial support provided to scientists, researchers, and organizations for conducting studies in the life sciences field. This increased funding has generated a growing interest in exosome research, particularly in the realms of disease diagnosis and therapeutic applications. The availability of funds has facilitated innovative approaches to exosome research, leveraging advanced technologies and methodologies to explore exosome biology and function. For instance, statistics from the National Center for Science and Engineering in September 2023 indicated a 13.6% increase in federal agency commitments for research and experimental development (R&D) in FY 2021, reaching an all-time high of $190.2 billion (in current dollars) from $167.4 billion in FY 2020. Thus, the rising funding for life sciences research is a driving force behind the growth of the exosome research market.

Product innovations emerge as a prominent trend gaining traction in the exosome research market, with major companies actively introducing inventive products to foster market growth. A case in point is the November 2022 launch by Cell Guidance Systems, a UK-based company, of Instant Exosomes and the LipoQ assay. Instant Exosomes, a subtype of extracellular vesicles (EV), are lipid membrane-enclosed compartments within the 50 to 1,000 nm diameter range. These EVs, released from various cell types and tissues, exhibit highly diverse contents. The LipoQ assay, based on the sulfo-phospo-vanillin method, facilitates the measurement of lipid content, particularly unsaturated fatty acids, within a given sample.

Major players in the exosome research market are strategically focusing on technological innovations, including the development of exosome characterization platforms, to gain a competitive advantage. These platforms encompass a set of tools and techniques dedicated to analyzing the physical, molecular, and functional properties of exosomes. Creative Biolabs Inc., a US-based biotech products and services provider, exemplifies this strategy by launching the Nanosight platform in August 2022. The Nanosight platform, designed specifically for exosome characterization, enhances accessibility and efficiency in exosome research for global researchers. It proves invaluable for researchers exploring the potential applications of exosomes in diverse fields such as medicine, diagnostics, and drug delivery.

In November 2021, Lonza, a Switzerland-based manufacturing company, acquired Codiak BioSciences for $65 million. This strategic acquisition aims to establish a Centre of Excellence focused on advancing exosome manufacturing technologies. Leveraging the strengths of both entities, the Centre of Excellence is poised to progress the production, purification, and analytics of exosomes. Lonza, through this collaboration, intends to offer customers services encompassing the development of exosome assays and processes, analytics, and manufacturing. Codiak BioSciences, a clinical-stage biopharmaceutical firm based in the United States, specializes in pioneering the development of exosome-based medicines.

Major companies operating in the exosome research market report are Thermo Fisher Scientific Inc., System Biosciences LLC, QIAGEN N.V., Exosome Diagnostics Inc., Bio-Techne Corporation, Hitachi Ltd., Aethlon Medical Inc., NanoSomiX Inc., Malvern Panalytical Ltd., Sistemic Scotland Limited, NX PharmaGen Corporation, Miltenyi Biotec GmbH, AMS Biotechnology (Europe) B.V., Norgen Biotek Corp., Novus Biologicals LLC, Lonza Group AG, Sistem-Bio S.A.S., Izon Science Ltd., Evomic Science LLC, New England Biolabs Inc., Evox Therapeutics Limited, Codiak BioSciences Inc., MagBio Genomics Inc., Cell Guidance Systems Ltd., Aruna Biomedical PBC, CureMetrix Inc., Capricor Therapeutics Inc., Stemcell Technologies Inc., ExoCoBio Inc., Creative Biolabs, ArcherDX Inc., Nanovex Biotechnologies S.L.

North America was the largest region in the exosome research market in 2023. The regions covered in the exosome research market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the exosome research market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary components of exosome research comprise kits and reagents, as well as instruments and other related tools. Kits and reagents are specialized test kits designed for use in laboratory settings or field environments to detect specific compounds. These kits find applications in various indications such as cancer, neurodegenerative diseases, cardiovascular diseases, infectious diseases, among others. Additionally, they serve different purposes such as biomarker identification, vaccine development, tissue regeneration, and more. End-users of these products include academic and research institutes, pharmaceutical and biotechnology companies, as well as hospitals and clinical testing laboratories.

The exosome research market research report provides exosome research market statistics, including exosome research industry global market size, regional shares, competitors with an exosome research market share, detailed exosome research market segments, market trends and opportunities, and any further data you may need to thrive in the exosome research industry. This exosome research market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The exosome research market consists of sales of exosome research tools, exosome isolation and detection tools, exosome marker antibodies, and exosome biomarkers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.